Cellaviva delivers stem cells to treat serious blood disease

April 1, 2022

Cordblood contains blood stem cells and is routinely used to treat severe diseasesof the blood and immune system. The treatment is similar to bone marrow stem celltherapy and the most common use of cord blood is sibling donation for thetreatment of childhood leukaemia.

NextCellowns the Cellaviva biobank, which has been helping pregnant parents savestem cells in connection with childbirth since 2015. The umbilical cord bloodthat is saved is the blood that remains in the placenta and umbilical cordafter the baby is born and the cord has been cut. In addition, a piece of theumbilical cord is also collected to grow connective tissue-forming stem cells.Haematopoietic stem cells can mature into all types of blood cells and immunecells, while connective tissue stem cells can mature into other tissues such ascartilage, fat and bone.

“ Thepurpose of preserving stem cells is not the saving itself, but to have rapidaccess to the highest quality stem cells in case of serious disease. Ourorganisation contributes to the development of new therapies and the expansionof treatment options for affected patients. Ultimately, it's about savinglives," says Mathias Svahn, vd NextCell.

Thecollection of stem cells from the umbilical cord does not alter the birthingprocess in any way and is risk-free. Currently, there are over 80 healthconditions with cord blood stem cells as an approved treatment option. In addition,experimental treatments using cord blood and cord tissue stem cells are beingevaluated for conditions such as cerebral palsy and type 1 diabetes. NextCellis conducting its own clinical trials with cells from donated umbilical cordsfor the treatment of type 1 diabetes and severe pneumonia caused by COVID-19.

For more information aboutCellaviva, please contact:

SofieFalk-Jansson, Commercial Director

Tel: 08-735 2010

E-mail: info@cellaviva.se

Webpage: www.cellaviva.se | www.cellaviva.dk

 

Instagram: https://www.instagram.com/cellaviva/

Facebook: https://www.facebook.com/cellavivasverige/

 

 

For more information about NextCell PharmaAB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel:08-735 5595

E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk

 

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

 

About NextCell Pharma AB

NextCell is a phase II cell therapy company withthe drug candidate ProTrans for the treatment of type 1 diabetes. The focus isto take ProTrans to market approval via a Phase III study. ProTrans is inaddition to diabetes, used in two clinical trials for Covid-19, in Örebro andMontreal (Canada). The company is in the processes of establishing its own GMPfacility for production of ProTrans. The GMP facility is expected to be readyfor production of smaller quantities of ProTrans in 2023. NextCell furthermoreowns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva,Scandinavia's largest stem cell bank for family saving stem cells fromumbilical cord blood and umbilical cord tissue with permission from the SwedishHealth and Social Care Inspectorate (IVO).

 

 

 

Download attachment
2022-10-27
NextCell presentation of Interim analysis data today at 15:00
NextCell Pharma AB ("NextCell" or the "Company") has developed a proprietary and patented platform technology where stem cells can be selected for allogeneic treatment of various specific diseases. CEO Mathias Svahn will present the results on Thursday, October 27 at 15:00 CET, which will be broadca
Read moreRead more
2022-10-27
NextCell publishes its Year-End Report 2021/2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2021 – August 31, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Marke
Read moreRead more
2022-10-24
NextCell cell therapy shows long-term effect in two independent diabetes studies "ProTrans-Repeat" and "ProTrans-Obs" – live presentation
NextCell Pharma AB ("NextCell" or the "Company") has developed a proprietary and patented platform technology where stem cells can be selected for allogeneic treatment of various specific diseases. CEO Mathias Svahn will present the results on Thursday, October 27 at 15:00 CET, which will be broad
Read moreRead more
2022-10-20
ProTrans cell therapy provides long-term effect in type-1 diabetes with a single treatment
NextCell Pharma AB ("NextCell" or the "Company") today announces that patients who 3 years ago were treated with ProTrans in the phase II study ProTrans-2 have maintained significantly higher endogenous insulin production than patients who received placebo, (63% compared to 23%). The results from th
Read moreRead more
2022-10-18
ProTrans cell therapy maintains insulin production effect 3.5 years after treatment
NextCell Pharma AB ("NextCell" or the "Company") today announces that type-1 diabetes patients receiving two treatments with a high dose of ProTrans cell therapy maintain a significantly higher endogenous insulin production than patients treated with low or medium doses.
Read moreRead more
2022-10-11
NextCell publishes opinion piece with ISCT
NextCell Pharma AB (”NextCell” or ”Company”) published an opinion piece on particulates in cell and gene therapy products with the International Society for Cell and Gene Therapy’s Process Development, Manufacturing and Analytics Committee last week in the journal Cytotherapy.
Read moreRead more
2022-09-28
NextCell updates on NLS days
NextCell Pharma AB ("NextCell" or the "Company") provides a status update today at the Nordic Life Science days in Malmö. NLS days is the Nordic region's largest partnering event in Life Science where NextCell's CEO Mathias Svahn will participate in meetings and give a presentation today at 14:12.
Read moreRead more
2022-08-25
ProTrans cell therapy to be granted patent protection beyond Europe
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Japan Patent Office (JPO) has issued a notice of allowance relating to the patent entitled "Allogeneic Composition" (publication number JP2020543858A). The patent describes the method of manufacturing the drug candidate ProTra
Read moreRead more